U.S. launches extensive Alzheimer's studies

January 14, 2013
U.S. launches extensive alzheimer's studies
5-year, $55 million effort will look at exercise, drug treatment as therapies for early disease.

(HealthDay)—Four U.S. government-funded clinical trials will search for new therapies for Alzheimer's disease.

The five-year effort will look at drug and exercise treatments for patients with early stage disease, test if the prazosin can reduce agitation in Alzheimer's patients, and examine a new approach to speed testing of drugs in .

The trials, which could cost as much as $55 million, are projects of the Alzheimer's Disease Cooperative Study (ADCS), a of and clinics established in 1991 by the U.S. National Institutes of Health.

The consortium, which includes more than 70 sites in the United States and Canada, focuses on research of diagnosis and treatment methods that might not be tested by the drug industry.

The four studies are among efforts to accomplish the research goals outlined in the National Plan to Address Alzheimer's Disease, which was announced in May 2012. The plan calls for a coordinated and focused effort in research, care and services for Alzheimer's and related types of . The goal is to find ways to prevent and effectively treat Alzheimer's by 2025.

"The ADCS is a key initiative in the federal program to discover, develop and test new Alzheimer's treatments and . Over the years, it has proved invaluable in advancing our understanding about the disease and how to conduct research in this challenging area," Dr. Richard Hodes, director of the National Institute on Aging, said in an NIH news release.

"I am particularly excited that this round of studies will use what we have learned by testing interventions pre-symptomatically, as early as we can in the development of the disease, where we now think the best hope lies for keeping Alzheimer's at bay," he added.

Explore further: Pfizer and J&J end development of Alzheimer's drug

More information: The Alzheimer's Association has more about Alzheimer's disease.

Related Stories

Pfizer and J&J end development of Alzheimer's drug

August 6, 2012
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.

US wants effective Alzheimer's treatment by 2025

January 17, 2012
The government is setting what it calls an ambitious goal for Alzheimer's disease: Development of effective ways to treat and prevent the mind-destroying illness by 2025.

Blood test for Alzheimer's: Study identifies procedure that detects early stages

May 4, 2011
(Medical Xpress) -- A new blood test that will diagnose Alzheimer's disease may soon hit the market, thanks to an innovative study from the Research Institute of the McGill University Health Centre (MUHC). Their findings ...

Looking for the anti-Alzheimer's molecule: A new approach to treating a devastating disease

November 7, 2012
Researchers at Dalhousie University have discovered a new technique using "computer-aided" drug design that may lead to an entirely new approach in the treatment of Alzheimer's disease (AD).

Trial set to see if drug can prevent Alzheimer's

May 16, 2012
(HealthDay) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

Recommended for you

Rocky start for Alzheimer's drug research in 2018

January 19, 2018
The year 2018, barely underway, has already dealt a series of disheartening blows to the quest for an Alzheimer's cure.

Alzheimer's disease: Neuronal loss very limited

January 17, 2018
Frequently encountered in the elderly, Alzheimer's is considered a neurodegenerative disease, which means that it is accompanied by a significant, progressive loss of neurons and their nerve endings, or synapses. A joint ...

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.